Welcome!

News Feed Item

Final Day of the 2014 BIO International Convention to Feature the Annual Scientific American WorldView Scorecard, BIO Idea Hackathon and Look at FDA’s Critical Path Initiative

The 2014 BIO International Convention, the world’s largest biotechnology event, enters its fourth and final day today at the San Diego Convention Center. Hosted by the Biotechnology Industry Organization, this year’s event is expected to attract more than 3,000 biotechnology companies and more than 15,000 attendees from 48 states and 65 countries.

Upcoming Convention Highlights Include:

  • Super Session: Scientific American WorldView Super Session - Biotech: We are the World, Thursday, June 26
    What is happening in biotechnology and life science development on the global stage? What are the most pressing issues of our time that have every nation looking to science as a solution? As the world continues to flatten, individual countries are finding new ways to grow their innovation engines, and in some cases, are hoping to outshine the US. Come to the annual Scientific American WorldView super session to hear a dynamic panel of international industry luminaries examine the future of global innovation in a lively candid conversation. Moderated by television and radio journalist, David Brancaccio, host of Marketplace Morning Report, this session will explore key themes from Scientific American’s annual biotechnology edition, featuring the WorldView Scorecard and fresh perspectives on international life science development.
  • Super Session: The Next Big Deal: The Global Dealmaker Perspective, Thursday, June 26
    2013 delivered in a big way for each of the major deal-making outlets with nearly three times the number of IPOs as in 2012. The M&A market opened up with the total dollars spent on acquisitions reaching the highest in five years. Strong deal terms with large upfront payments for early stage assets were also seen in 2013 as exemplified with Moderna’s $240M upfront from Astrazeneca and Oncomed’s $177M upfront from Celgene. Will these upward trends continue? How will these changing dynamics impact dealmaking in the coming year? What do dealmakers expect will be the result in 2014? Campbell Alliance and BIO are pleased to present updated findings from two unique forward-looking measures of dealmaking in the industry – the Campbell Alliance Dealmakers’ Intentions Study and the BIO One-on-One Partnering Forecast. Based on a survey of more than 150 industry executives, business development professionals, and financial institutions, Dealmakers’ Intentions provides insight into what will likely drive the industry’s partnering and M&A efforts moving forward, and the implications for deal-making over the next year or more. Now in its sixth year, new analysis in 2014 will include year-over-year trends, additional deal metrics, and broader M&A data. Incorporating a global perspective, a highly distinguished panel of dealmakers will then explore the impact these market forces will have on pharmaceutical and biotech companies as they position themselves to make that next big deal.
  • New Technologies to Save Us In a Disaster: Opportunities in the Public-Private Partnership to Develop Medical Countermeasures, Thursday, June 26
    In the decade since the US Congress adopted Project Bioshield, more than $5 billion has been invested in the biodefense sector. This session will explore recent trends and new developments in the advanced development of medical countermeasures (MCMs). The session will provide an update on the status of the Centers of Innovation for Advanced Development and Manufacture and opportunities for drug developers. It will also provide perspectives on the need for novel technologies and key considerations for companies entering the biodefense sector as it matures.
  • The Salford Lung Study: An Innovative 'Real World' Study Design for Chronic Conditions, Thursday, June 26
    The 12-month Salford (UK) Lung Study uses an integrated electronic patient record to assess the safety and effectiveness of Relovair, GlaxoSmithKline's late-phase follow-up to Advair, in chronic obstructive pulmonary disease and asthma. Results are intended to help healthcare decision- makers better assess the drug's potential at an earlier stage. The panel will address the complexities of “real-world” studies and how healthcare providers and regulators can use the data generated to understand the benefits of such studies, particularly for chronic conditions managed in community settings.
  • FDA's Critical Path Initiative: Progress in the First Decade and Promise for the Next, Thursday, June 26
    In 2004, the FDA launched the Critical Path Initiative (CPI), which was a response to the needs and challenges faced by medical product developers. Recognizing that no one organization possesses the resources and expertise to solve medical product development problems, the CPI called for a consortium or public-private-partnership approach to modernize the process whereby FDA-regulated products are developed and evaluated. A brief videotaped overview of the CPI will be provided by its chief architect, Dr. Janet Woodcock (CDER/FDA). Then speakers from the FDA, and industry and non-profit organizations will reflect on certain aspects of CPI that have been accomplished through consortia, present the challenges faced by organizations working in the "pre-competitive" space, and explore options for optimizing future collaborations.
  • Biotech Battle of the Wits 2014, Thursday, June 26
    Back for its third year, well-known biotech journalist Chris Morrison will emcee this rapid-fire, interactive debate on the industry’s hot-button issues featuring three biotech trendsetters. Listen as panelists provide their off-the-cuff opinions on the industry’s most controversial and topical issues. What is the strangest biotech idea you’ve come across? How can a company bounce back from a Phase III failure? To drive the debate, audience members can ask questions live or via Twitter (@BioBanter) and vote for presenters online via Twitter or text. The winner of this session will receive 120 uninterrupted seconds to sound off on the topic of their choice.
  • BIO Career Fair, Thursday, June 26
    The 2014 BIO Career Fair is free to all job seekers. Co-located with the 2014 BIO International Convention, the BIO Career Fair will give attendees access to many of the world’s leading life science companies.

Day Three Session Highlights Included:

Follow the 2014 Convention @BIOConvention, and join the conversation @IAmBIOtech.

The Convention program features more than 160 sessions in 8 breakout sessions and 9 specialty forums. The majority of attendees, 70 percent, are c-level executives. They split evenly from large companies of 500 or more employees and small companies of 50 employees or less.

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on major trends affecting the industry. The Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. Visit http://convention.bio.org/program/ for the most up-to-date program and speaker information.

The Convention also features the BIO Business Forum, which has grown over the past thirteen years to become the industry's largest partnering event. This year’s Convention is set to break all previous partnering records, with over 28,000 meetings expected to take place. Powered by BIO's One-on-One Partnering™ System, the BIO Business Forum™ fosters the opportunity for companies to initiate business contacts in a friendly environment and schedule private meetings prior to the Convention.

Upcoming BIO Events

BIO Latin America Conference
September 9-11, 2014
Rio de Janeiro, Brazil

Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

For more information:
Visit http://www.bio.org
Follow us on Twitter @IAmBiotech
Join us on LinkedIn/MyBio
Become a fan at facebook.com/IAmBiotech

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Cloud analytics is dramatically altering business intelligence. Some businesses will capitalize on these promising new technologies and gain key insights that’ll help them gain competitive advantage. And others won’t. Whether you’re a business leader, an IT manager, or an analyst, we want to help you and the people you need to influence with a free copy of “Cloud Analytics for Dummies,” the essential guide to this explosive new space for business intelligence.
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, provided tips on how to be successful in large scale machine learning...
Early adopters of IoT viewed it mainly as a different term for machine-to-machine connectivity or M2M. This is understandable since a prerequisite for any IoT solution is the ability to collect and aggregate device data, which is most often presented in a dashboard. The problem is that viewing data in a dashboard requires a human to interpret the results and take manual action, which doesn’t scale to the needs of IoT.
What does it look like when you have access to cloud infrastructure and platform under the same roof? Let’s talk about the different layers of Technology as a Service: who cares, what runs where, and how does it all fit together. In his session at 18th Cloud Expo, Phil Jackson, Lead Technology Evangelist at SoftLayer, an IBM company, spoke about the picture being painted by IBM Cloud and how the tools being crafted can help fill the gaps in your IT infrastructure.
"C2M is our digital transformation and IoT platform. We've had C2M on the market for almost three years now and it has a comprehensive set of functionalities that it brings to the market," explained Mahesh Ramu, Vice President, IoT Strategy and Operations at Plasma, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
Traditional IT, great for stable systems of record, is struggling to cope with newer, agile systems of engagement requirements coming straight from the business. In his session at 18th Cloud Expo, William Morrish, General Manager of Product Sales at Interoute, outlined ways of exploiting new architectures to enable both systems and building them to support your existing platforms, with an eye for the future. Technologies such as Docker and the hyper-convergence of computing, networking and sto...
SYS-CON Events announced today that LeaseWeb USA, a cloud Infrastructure-as-a-Service (IaaS) provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LeaseWeb is one of the world's largest hosting brands. The company helps customers define, develop and deploy IT infrastructure tailored to their exact business needs, by combining various kinds cloud solutions.
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
It’s 2016: buildings are smart, connected and the IoT is fundamentally altering how control and operating systems work and speak to each other. Platforms across the enterprise are networked via inexpensive sensors to collect massive amounts of data for analytics, information management, and insights that can be used to continuously improve operations. In his session at @ThingsExpo, Brian Chemel, Co-Founder and CTO of Digital Lumens, will explore: The benefits sensor-networked systems bring to ...
Much of IT terminology is often misused and misapplied. Modernization and transformation are two such terms. They are often used interchangeably even though they mean different things and have very different connotations. Indeed, it is somewhat safe to assume that in IT any transformative effort is likely to also have a modernizing effect, and thus, we can see these as levels of improvement efforts. However, many businesses are being led to believe if they don’t transform now they risk becoming ...